Clinical trials of antiangiogenic agents

Przemyslaw Twardowski*, William J. Gradishar

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


Acquisition of new blood vessels is a required step in malignant transformation, tumor growth, and metastasis. Inhibition of angiogenesis is one of the most promising new strategies for the treatment of malignant neoplasms. In recent years, several antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and tecogalan sodium, have entered clinical trials. In this we review, we look at the results of early clinical trials of these agents and discuss the new angiogenesis inhibitors in preclinical development.

Original languageEnglish (US)
Pages (from-to)584-589
Number of pages6
JournalCurrent opinion in oncology
Issue number6
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical trials of antiangiogenic agents'. Together they form a unique fingerprint.

Cite this